Statins and proteinuria
The proteinuria associated with 3-hydrodoxy-3-methylglutaryl coenzyme A reductase inhibitors is composed of primarily low-molecular weight proteins that disappear rapidly following discontinuation of the statin agent. More importantly, no evidence exists of nephrotoxicity or reduced renal function observed with the approved clinical dosages of any available statins. Recent clinical studies have suggested actual improvement in renal function demonstrated by decreases in creatinine concentrations and improvement in estimated glomerular filtration rates with both short-term and long-term administration of these agents. The progressive fibrosis and renal scarring of chronic kidney disease appears to be the end result of increased protein traffic in the proximal renal tubule. Early animal and recent clinical studies have suggested that treatment with statin agents in established chronic kidney disease can, in fact, provide renoprotection over and above that observed with aggressive blood pressure control and the use of angiotensin II antagonists.
Unable to display preview. Download preview PDF.
- 3.Novikoff AB: The rat kidney; cytochemical and electron microscopic studies. In Ciba Foundation Symposium, Edited by Quinn EL, Kass EK. Boston: Little, Brown; 1960; 113–144.Google Scholar
- 5.Maack T: Renal filtration, transport and metabolism of protein. In The Kidney, edn 3. Edited by Seldin DW, Giebish G. Philadelphia: Lippincott, Williams & Wilkins; 2000: 2235–2267.Google Scholar
- 19.Endocrinologic and Metabolic Drugs Advisory Committee, July 9 2003, Food and Drug Administration Center for Drug Evaluation and Research. Department of Health and Human Services. 2003, Available at http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3968T1.doc. Accessed July 5, 2004.Google Scholar
- 20.Pharmacology/Toxicology. DNA 21-366 Crestor July 9, 2003. Advisory Committee Briefing Document. Department of Health and Human Services. 2004. Available at http://www.fda.gov.ohrms/dockets/ac/03/briefing/3968B1 02 F-FDA-Pharm Tox%20Review.pdf. Accessed on July 5, 2004.Google Scholar
- 24.Athyros VG, Mikhailidis DP, Papageorgiou AA, et al.: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation GREACE. study. J Clin Pathol 2004, 57:728–734.PubMedCrossRefGoogle Scholar
- 30.Comper WD, Osicka TM: Albumin-like material in urine. Kidney Int Suppl 2004, S65–S66.Google Scholar
- 39.Liang K, Vaziri ND: HMG-CoA reductase inhibition with rosuvastatin improves hyperlipidemia and proteinuria and reverses LDL receptor and HDL receptor deficiencies in the nephrotic syndrome [abstract]. J Am Soc Nephrol 2003, 14:168A.Google Scholar
- 49.Sposito AC, Mansur AP, Coelho OR, et al.: Additional reduction in blood pressure after cholesterol-lowering treatment by statins lovastatin or pravastatin. in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors enalapril or lisinopril. Am J Cardiol 1999, 83:1497–1499.PubMedCrossRefGoogle Scholar